Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

被引：1
|
作者：
Lee, Angela
Oley, Frank, Jr.
Lo, Mimi
Fong, Richard
McGann, Mary
Saunders, Ila
Block, Shanna
Mahajan, Anjlee
Pon, Tiffany
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-138635
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?
    Howlett, Jennifer
    Benzenine, Eric
    Fagnoni, Philippe
    Quantin, Catherine
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (03) : 642 - 651
  • [22] Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism
    Park, Deborah Y.
    Poudel, Shyam K.
    Jia, Xuefei
    Wilks, Mailey Lynn
    Pinkava, Vicki
    O'Brien, Meghan
    Tripp, Barbara
    Song, Jung-Min
    McCrae, Keith R.
    Angelini, Dana E.
    Khorana, Alok A.
    BLOOD, 2018, 132
  • [23] Healthcare resource utilization and costs after initiating direct-acting oral anticoagulants or low molecular weight heparins in patients with venous thromboembolism
    Okoye, Godwin
    Ben-Umeh, Kenechukwu C.
    Avancena, Anton L., V
    Onukwugha, Eberechukwu
    VASCULAR MEDICINE, 2025,
  • [24] Low Molecular Weight Heparin (LMWH) for Venous Thromboembolism (VTE) Prophylaxis in Patients with Primary Central Nervous System Lymphoma (PCNSL)
    Rund, Deborah
    Gazal, Stav
    Kalish, Yosef
    Makranz, Chen
    Goldschmidt, Neta
    BLOOD, 2018, 132
  • [25] PREVALENCE AND FACTORS ASSOCIATED WITH THE USE OF DIRECT ORAL ANTICOAGULANTS ANDLOW MOLECULAR WEIGHT HEPARINS (LMWH) IN CANCER PATIENTS
    Johnson, M. L.
    Yande, S.
    Aparasu, R. R.
    Wanat, M.
    Toale, K.
    VALUE IN HEALTH, 2023, 26 (06) : S377 - S378
  • [26] Thrombin generation (TG) is downregulated by low molecular weight heparin (LMWH) in cancer patients with venous thromboembolism (VTE)
    Falanga, A.
    Tartari, C.
    Marchetti, M.
    Russo, L.
    Lambregts, K. W.
    Resta, D.
    D'Alessio, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 817 - 817
  • [27] Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants
    Uppuluri, Ellen M.
    Burke, Kelly R.
    Haaf, Christina Mactal
    Shapiro, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (02) : 261 - 268
  • [28] Direct Oral Anticoagulants and Low-Molecular Weight Heparin for Primary Prevention of Venous Thromboembolism in Cancer Patients: A Meta-Analysis
    Mulles, A.
    Nicolas, A. L.
    Chiu, H. C.
    Villalobos, R. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [29] Direct oral anticoagulants and low-molecular weight heparin for primary prevention of venous thromboembolism in cancer patients: a meta-analysis
    Mulles, Anna Francesca
    Nicolas, Amraphel
    Chiu, Harold Henrison
    Villalobos, Ralph Elvi
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [30] Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain
    Munoz, Andres
    Gallardo, Enrique
    Agnelli, Giancarlo
    Crespo, Carlos
    Forghani, Monica
    Arumi, Daniel
    Fernandez de Cabo, Susana
    Soto, Javier
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 840 - 847
12345